Combining Treatment Components in Transdiagnostic Therapy for Anxiety and Depression
NCT06429956, Not applicable, Recruiting, University of Aarhus
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Combining Treatment Components in Transdiagnostic Therapy for Anxiety and Depression | ClinicalTrials.gov |
| NCT number | NCT06429956 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 93 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | University of Aarhus | ClinicalTrials.gov |
| Conditions | Depression, Anxiety | ClinicalTrials.gov |
| Interventions | Mindful emotion awareness, Cognitive flexibility | ClinicalTrials.gov |
| First posted | 2024-05-28 | ClinicalTrials.gov |
| Last updated | 2025-11-28 | ClinicalTrials.gov |
Registered outcomes 29
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Depressive symptoms (PHQ-9) | Development from pre-treatment to post-treatment (6 weeks) | Patient Health Questionnaire-9 (PHQ-9; Kroenke et al., 2001; Spitzer et al., 1999; Spitzer et al., 2000). | ClinicalTrials.gov |
| Primary | Anxiety symptoms (BAI) | Development from pre-treatment to post-treatment (6 weeks) | Beck's Anxiety Inventory (BAI; Beck et al., 1988; Beck \& Steer, 1991). | ClinicalTrials.gov |
| Primary | Symptoms of generalized anxiety disorder (GAD-7) | Development from pre-treatment to post-treatment (6 weeks) | The General Anxiety Disorder-7 (GAD-7; Spitzer et al., 2006). | ClinicalTrials.gov |
| Primary | Symptoms of social anxiety disorder (SIAS) | Development from pre-treatment to post-treatment (6 weeks) | The Social Interaction Anxiety Scale (SIAS; Mattick \& Clarke, 1998). | ClinicalTrials.gov |
| Primary | Symptoms of panic disorder (PDSS-SR) | Development from pre-treatment to post-treatment (6 weeks) | The Panic Disorder Severity Scale - Self-Report Version (PDSS-SR; Houck et al., 2002). | ClinicalTrials.gov |
| Secondary | Depressive symptoms (PHQ-9) | Development from pre-treatment through 3-month follow-up | Patient Health Questionnaire-9 (PHQ-9; Kroenke et al., 2001; Spitzer et al., 1999; Spitzer et al., 2000). | ClinicalTrials.gov |
| Secondary | Anxiety symptoms (BAI) | Development from pre-treatment through 3-month follow-up | Beck's Anxiety Inventory (BAI; Beck et al., 1988; Beck \& Steer, 1991). | ClinicalTrials.gov |
| Secondary | Symptoms of generalized anxiety disorder (GAD-7) | Development from pre-treatment through 3-month follow-up | The General Anxiety Disorder-7 (GAD-7; Spitzer et al., 2006). | ClinicalTrials.gov |
| Secondary | Symptoms of social anxiety disorder (SIAS) | Development from pre-treatment through 3-month follow-up | The Social Interaction Anxiety Scale (SIAS; Mattick \& Clarke, 1998). | ClinicalTrials.gov |
| Secondary | Symptoms of panic disorder (PDSS-SR) | Development from pre-treatment through 3-month follow-up | The Panic Disorder Severity Scale - Self-Report Version (PDSS-SR; Houck et al., 2002). | ClinicalTrials.gov |
| Secondary | Quality of life (WHO-5) | Development from pre-treatment to post-treatment and development from pre-treatment through 3-month follow-up | The World Health Organization (WHO)-5 questionnaire (Bech, 1999; Topp et al., 2015). | ClinicalTrials.gov |
| Secondary | Rumination (RRS brooding subscale) | Development from pre-treatment to post-treatment and development from pre-treatment through 3-month follow-up | The Ruminative Response Scale (RRS) brooding subscale (Treynor et al., 2003). | ClinicalTrials.gov |
| Secondary | Worry (PSWQ) | Development from pre-treatment to post-treatment and development from pre-treatment through 3-month follow-up | The Penn State Worry Questionnaire (PSWQ; Meyer et al., 1990). | ClinicalTrials.gov |
| Secondary | Worry (AWS) | Session by session development during the 6 weeks of active treatment | For in-session questionnaires, the Ambulatory Worry Scale (AWS; Kramer et al., 2021) will be used because it has been specially developed to evaluate state variations in worry. | ClinicalTrials.gov |
| Secondary | Decentering (EQ decentering subscale) | Development from pre-treatment to post-treatment and development from pre-treatment through 3-month follow-up | The Experiences Questionnaire (EQ) decentering subscale (Fresco et al., 2007). | ClinicalTrials.gov |
| Secondary | Reappraisal (ERQ) | Development from pre-treatment to post-treatment and development from pre-treatment through 3-month follow-up | Emotion Regulation Questionnaire (ERQ) reappraisal subscale (Gross \& John, 2003). | ClinicalTrials.gov |
| Secondary | Mindfulness (FFMQ-15) | Development from pre-treatment to post-treatment and development from pre-treatment through 3-month follow-up | Five Facet Mindfulness Questionnaire - 15 (FFMQ-15; Baer et al., 2006). | ClinicalTrials.gov |
| Secondary | Subjective cognitive function (PDQ-D) | Development from pre-treatment to post-treatment and development from pre-treatment through 3-month follow-up | Perceived Deficits Questionnaire - Depression (PDQ-D; Fehnel et al., 2016) | ClinicalTrials.gov |
| Secondary | Experience of therapy | Session by session development during the 6 weeks of active treatment and through 3-month follow-up | Five questions concerning the participants' experience or expectations concerning the components have been developed by the project group due to a lack of such assessment in the field. | ClinicalTrials.gov |
| Secondary | Working alliance (WAI-SR) | Session 3 and 5 only | Working Alliance Inventory - Short Revised (WAI-SR; Munder et al., 2010). | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 5
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Digit Span Test | Other outcome | ConductCognition |
| Stroop Color-Word Test | Other outcome | ConductCognition |
| Trail Making Test A | Other outcome | ConductCognition |
| Trail Making Test B | Other outcome | ConductCognition |
| Verbal Fluency | Other outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)